Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney DiseaseDick de Zeeuw, Glenn M. Chertow, Janet Wittes et al.|New England Journal of Medicine|2013Cited by 990
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceIain C. Macdougall, Elena Zakharova, Yusuke Tsukamoto et al.|Kidney International|2016Cited by 474
Sleep quality predicts quality of life and mortality risk in haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)S. J. Elder, Rajiv Saran, R. L. Pisoni et al.|Nephrology Dialysis Transplantation|2007Cited by 322
Japanese Society for Dialysis Therapy Clinical Guideline for “Hemodialysis Initiation for Maintenance Hemodialysis”Yuzo Watanabe, Kunihiro Yamagata, Shinichi Nishi et al.|Therapeutic Apheresis and Dialysis|2015Cited by 86
Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non‐insulin‐dependent Otsuka Long‐Evans Tokushima Fatty ratsYoshihiro Kuno, Tadao Akizawa|British Journal of Pharmacology|2010Cited by 72